The FDA has started a priority review of Chiesi 's velmanase alfa, an enzyme replacement therapy for lysosomal storage disease (LSD) alpha-mannosidosis, with a decision expected in the first half ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback